Dyslipidemia clinical practice treatment charasteristics and perspectives of statins lipidlowering therapy effiecency upgrade

Abstract

Cardiovascular diseases caused by atherosclerosis and thrombosis continue to be the main causes of hospitalizations, disability and mortality rates throughout the world. Their development depends on many factors, among which the leading role belongs to dyslipidemia. It is well known that dyslipidemia is extremely heterogeneous and includes a wide range of disorders that are of great importance in the development and progression of cardiovascular diseases. Therefore, the correction of dyslipidemia is an essential element in reducing the risk of cardiovascular complications. Of all the classes of hypolipidemic agents, statins have the greatest evidence base for improving outcomes of cardiovascular diseases. A huge number of controlled clinical trials performed with these drugs, as well as a long experience of their real use in the clinic, made it possible to rather strictly formulate the basic principles of their use and control over their effectiveness and safety. Thus, assessment of the quality of therapy with statins and its compliance with the recommendations is an urgent task. In clinical practice, many patients with indications do not receive statins at all or rarely achieve «target values» of lipids, including due to low adherence to prescribed therapy. In addition, some doctors in practice do not always adhere to the requirements of clinical recommendations. Numerous studies conducted in various countries have shown that the measures taken to correct the risk factors for cardiovascular diseases are not sufficiently adequate and effective. This problem in one degree or another exists in all countries, but in Russia it is particularly relevant.

Keywords

cardiovascular risk factors / dyslipidemia / prevention / pharmacotherapy / statins / the actual clinical practice / the european study on cardiovascular risk prevention and management in usual daily practice / centralized pan-middle east survey on the undertreatment of hypercholesterolemia

References

[1] Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (шестой пересмотр). – М., 2017. – 22 с.

[2] Концевая, А.В. Экономический ущерб сердечно-сосудистых заболеваний в Российской Федерации в 2016 г. / А.В. Концевая [и др.] // Рациональная фармакотерапия в кардиологии. – 2018. – № 14. – С. 156–166.

[3] Марцевич, С.Ю. Наблюдение в специализированном медицинском центре и качество гиполипидемической терапии у пациентов с сердечно-сосудистыми заболеваниями (по данным регистра ПРОФИЛЬ) / С.Ю. Марцевич [и др.] // Рациональная фармакотерапия в кардиологии. – 2013. – Т. 9, № 2. – С. 133–137.

[4] Марцевич, С.Ю. Реальная практика назначения статинов и ее зависимость от наблюдения в специализированном медицинском центре у больных с высоким риском сердечно-сосудистых осложнений (по данным регистра ПРОФИЛЬ) / С.Ю. Марцевич [и др.] // Рациональная фармакотерапия в кардиологии. – 2013. – Т. 9, № 4. – С. 362–367.

[5] Национальные рекомендации. Кардиоваскулярная профилактика // Кардиоваскулярная терапия и профилактика. – 2017. – № 6. –122 с.

[6] Пучиньян, Н.Ф. Современные статины в первичной и вторичной профилактике сердечно-сосудистых заболеваний / Н.Ф. Пучиньян, Я.П. Довгалевский, А.В. Панина // Рациональная фармакотерапия в кардиологии. – 2012. – Т. 8, № 4. – С. 538–544.

[7] Рекомендации Европейского общества кардиологов и Европейского общества атеросклероза по лечению дислипидемий // Рациональная фармакотерапия в кардиологии. – 2012. – При- лож. № 1. – С. 3–63.

[8] Российский статистический ежегодник. Статистический сборник. – М., 2018. – 694 с.

[9] Сусеков, А.В. Основные результаты Московского исследования по статинам (Moscow Statin Survey, MSS) / Сусеков А.В. [и др.] // Сердце. – 2006. – № 6. – С. 324–328.

[10] Толпыгина, С.Н. Лечение пациентов с хронической ишемической болезнью сердца в реальной клинической практике по данным регистра «ПРОГНОЗ ИБС» (часть 1) / С.Н. Толпыгина, Ю.Н. Полянская, С.Ю. Марцевич // Рациональная фармакотерапия в кардиологии. – 2013. – Т. 9, № 2. – С. 138–142.

[11] Alberts, MJ. Reduction of Atherothrombosis for Continued Health Registry Investigators. Three-year followup and event rates in the international Reduction of Atherothrombosis for Continued Health Registry / M.J. Alberts [et al.] // Eur Heart J. – 2009. – Vol. 30. P. 2318–2326.

[12] Baigent, C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials / C. Baigent [et al.] // Lancet. – 2010. – Vol. 376, № 9753. – P. 1670–1681.

[13] Banegas, J.R. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study / Banegas J.R. [et al.] // Eur. J. Cardiovasc. Preven. Rehabilit. – 2011. – Vol. 32. – P. 2143–2152.

[14] Bertuccio, P. Coronary heart disease and cerebrovascular disease mortality in young adults: recent trends in Europe / P. Bertuccio [et al.] // Eur. J. Cardiovasc. Preven. Rehabilit. – 2011. – Vol. 18. – P. 627–634.

[15] Bhatt, DL. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis / D.L. Bhatt [et al.] // JAMA – 2006. – P. 180–189.

[16] Conroy, R.M. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project / R.M. Conroy [et al.] // European Heart Journal. – 2003. – Vol. 24. – P. 987–1003.

[17] Dallongeville, J. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study / J. Dallongeville [et al.] // European Journal of Preventive Cardiolohgy. – 2011. – Vol. 19. – P. 541–550.

[18] EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention in coronary heart disease, principal result. / Eur. J. Heart. – 1997. Vol. 18. – Р. 82–1569

[19] Graham, I. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) / I. Graham [et al.] // Eur. J. Cardiovasc Prev Rehabil. – 2007. – P.1–113.

[20] Hermans, M.P. Centralized Pan-European survey on the under- treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries / M.P. Hermans [et al.] // Curr. Med. Res. Opin. – 2010. – Vol. 26. – P. 445–454.

[21] Julian D. Translation of clinical trials into clinical practice. Journal of Internal Medicine. – 2004. – № 255. – P. 309–316

[22] Lawes, C.M. International Society of Hypertension. Global burden of blood-pressure-related disease (2001) / C.M. Lawes [et al.] // Lancet. – 2008. – Vol. 371, № 9623. – P. 1513–1518.

[23] Lipson, A. Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events / A.H. Lipson [et al.] // Can Fam Physician. – 2007. – Vol. 53. – P. 1502–1507.

[24] Neaton, J. Recruitment of Participants for the Multiple Risk Factor Intervention Trial (MRFIT) / J. Neaton [et al.] // Control. Clin. Trials. – 1987. – Vol. 8. – P. 41–53.

[25] O’Donnell, M. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE Study): a case-control study Reference / M.O’Donnell [et al.] // Lancet. – 2010. – Vol. 376. – P. 112–123.

[26] Rodríguez-Artalejo, F. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA) / F. Rodríguez-Artalejo [et al.] // BMC Public Health. – 2010. – № 10. – P. 382.

[27] Stamler, J. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) / J. Stamler [et al.] // JAMA. – 1986. – Vol. 256, № 20. – P. 2823–2828.

[28] Yusuf, S. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case-control study / S. Yusuf [et al.] // Lancet. – 2004. – Vol. 364, № 9438. – Р. 937–952.

[29] Yusuf, S. Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs forcardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey / S. Yusuf [et al.] // Lancet. – 2011. – Vol. 378, № 9798. – P. 43–1231.

RIGHTS & PERMISSIONS

Eco-Vector